Japanese Pharma major Takeda had announced its intention to take over Belgian adipose stem cell therapy specialist Tigenix, which has already exclusively licenced its lead product darvadstrocel (Cx601) to treat Crohn’s disease. In December darvadstrocel received a recommendation from the European Medicines Agency to market the product in Europe in patients with complex perianal fistulas, one of the most disabling manifestations of Crohn’s disease.
Ablynx rejects Novo’s €2.3bn bid
Latest NewsNanobody developer Ablynx NV has stated that the take-over cash price of €28 per share + optional €2.50 per share as Contingent Value Right (CVR) offered by Novo Nordisk A/S at the end of December is too low. The bid valued Ablynx at €2.3bn.
Cancer data: a dive into the depths
BackgroundAs Big Data analytics begin to inspire medical decisionmaking, companies and scientists have gone to war over access to data derived from patient biopsies. Cancer profiling is a seminal situation. While some companies are seeking to profit from approaches to advanced mutation analysis, researchers are vociferous in demanding open access to proprietary databases behind company firewalls.
Sterna Biologicals appoints CEO
Appointmentssterna biologicals GmbH & Co. KG announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer.
Roche further expands in digital medicine
Latest NewsGlobal theranostics major Roche expands its digitalised medicine portfolio. The next agreed project is a digital diagnostics platform to improve oncology and critical care treatment.
Sanifit appoints Cris Calsada as CFO
AppointmentsLaboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.
Targovax appoints Michael Bogenstaetter as CBO
AppointmentsTargovax ASA (OSE: TRVX) announces that Michael Bogenstaetter has been appointed as the Company’s Chief Business Officer (CBO). He will take up this role in January 2018.
New method identifies harmful medicines metabolites
Latest NewsA new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body has been developed by researchers at Cardiff University.
Takeda bids €520m for TiGenix
Latest NewsJapanese Pharma major Takeda had announced its intention to take over Belgian adipose stem cell therapy specialist Tigenix, which has already exclusively licenced its lead product darvadstrocel (Cx601) to treat Crohn’s disease. In December darvadstrocel received a recommendation from the European Medicines Agency to market the product in Europe in patients with complex perianal fistulas, one of the most disabling manifestations of Crohn’s disease.
Boehringer Ingelheim expands Venture Funds to €250m
Latest NewsGerman human and veterinay medicines major Boehringer Ingelheim has more than doubled the amount in funding of its Venture Fund (BIVF) to €250m. Additionally, the investment focus has been extended to include infectious diseases and digital health.
Addex inks US$339m deal with Indivior
Latest NewsSwiss allosteric modulation specialist Addex Therapeutics has licenced its GABA modulator ADX71441 to US addiction therapeutics expert Indivior plc.